ReviewResearch (Washington, D.C.)2025
Alternative Splicing: A Critical Regulator in Human Bone Biology and Tumor Progression.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Temporal-responsive hydrogels reprogramming energy metabolic pathway in the bone-angiogenic cascade for diabetic bone regeneration.Materials today. Bio · 2026Article
- Nuclear Mechanics and Nuclear Mechanotransduction in Cancer Cell Migration and Invasion.Biomolecules · 2026Review
- Integrative Single-Cell RNA Sequencing and Machine Learning Reveals Candidate Plasma Protein-Associated Gene Signatures for Osteoporosis: A Preliminary Exploratory in Silico Study.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative splicing (AS) is the central mechanism of transcriptional regulation and generates diverse splice variants that influence protein structure, function, and intracellular activity. AS plays critical roles in tissue differentiation, organ development, and disease progression. This review focuses on the pivotal roles of AS in bone biology, highlighting its regulatory effects on osteoblasts, osteoclasts, chondrocytes, bone matrix remodeling, and bone remodeling, as well as the involvement of AS-related RNA-binding proteins in these processes. We also emphasize bone-specific AS events and their physiological importance in skeletal development and maintenance. Furthermore, the pathological role of AS is emphasized in bone-related tumors such as osteosarcoma, Ewing sarcoma, and chondrosarcoma. This review also explores aberrant AS mechanisms in bone metastatic cancers, including prostate, bladder, and breast cancers, with an in-depth analysis of their roles in tumor progression and alterations in the bone microenvironment. This review provides a comprehensive perspective on how AS factors, signaling pathways, and mechanical stimulation collaboratively regulate bone cells under both physiological and pathological conditions, paving the way for identifying potential intervention strategies. The mechanisms of AS in other pathological bone conditions, such as osteoporosis, osteoarthritis, and hereditary bone disorders, are also summarized. The potential applications of targeting AS in the diagnosis and treatment of bone diseases are discussed, offering insights into the underlying mechanisms and clinical translational potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.